[1]
|
Jasinski, D.R., Pevnick, J.S. and Griffith, J.D. (1978) Human pharmacology and abuse potential of the analgesic buprenorphine. Archives of General Psychiatry, 35(4), 501-516.
|
[2]
|
Lewis, J.W. (1985) Buprenorphine. Drug and Alcohol Dependence, 14(3-4), 363-372.
|
[3]
|
Hambrook, J.M. and Rance, M.J. (1976) The interaction of buprenorphine with opiate receptor. In: Kosterlitz, H.W., Ed., Opiates and Endogenous Opioid Peptides, Elsevier/North Holland Biomedical Press, Amsterdam, 295-301.
|
[4]
|
Adrianensen, H., Mattlaer, B. and Vanmeenen, H. (1985) A longtermopen, clinical and pharmacokinetic assessment of sublingual buprenorphine in patients suffering from chronic pain. Acta Anaesthesiologica, 36(1), 33-40.
|
[5]
|
Amass, L., Bickel, W.K., Higgins, S.T. and Badger, G.J. (1994) Alternate-day dosing during buprenorphine treatment of opoid dependence. Life Science, 54(17), 1215- 1228.
|
[6]
|
Strain, E.C., Stitzer, M.L., Liebson, L.A. and Bigelow, G.E. (1994) Comparison of buprenorphine and methadone in the treatment of opiod dependence. American Journal of Psychiatry, 151(7), 1025-1030.
|
[7]
|
Downing, J.W., Leary, W.P. and White, E.S. (1977) Buprenorphine: A new potent long-acting synthetic analgesic. Comparison with morphine. British Journal of Anaesthesia, 49(3), 251-255.
|
[8]
|
Bullingham, R.E.S., McQuay, H.J., Moore, A. and Bennett, M.D.R. (1980) Buprenorphine kinetics. Clinical Pharmacology & Therapeutics, 28(5), 667-672.
|
[9]
|
Walsh, S.L, Preston, K.L., Stitzer, M.L., Cone, E.J. and Bigelow, G.E. (1994) Clinical Pharmacology of buprenorphine: Ceiling effects at high doses, Clinical Pharmacology & Therapeutics, 55(5), 569-580.
|
[10]
|
Evans, H.C. (2003) Transdermal buprenorphine. Drugs, 63(19), 1999-2010.
|
[11]
|
Park, I., Kim, D.W., Song, J.D., In, C.H., Jeong, S.W., Lee, S.H., Min, B.C., Lee D.H. and Kim, S.O. (2008) BupredermTM, a new transdermal delivery system of buprenorphine: Pharmacokinetic, efficacy and skin irritancy studies. Pharmaceutical Research, in press.
|
[12]
|
Perez-Urizar, J., Granados-Soto, V. and Flores-Murrieta, F.J. (2000) Pharmacokinetic-pharmacodynamic modeling: Why? Archives of Medical Research, 31(6), 539-545.
|
[13]
|
Van der Graaf, P.H. and Danhof, M. (1997) Analysis of frug-receptor interactions in vivo: A new approach in pharmacokinetic-parmacodynamic modeling. International Journal of Clinical Pharmacology, Therapy & Toxicology, 35, 442-446.
|
[14]
|
Gopal, S., Tzeng, T-B. and Cowan, A. (2002) Characterization of the pharmacokinetics of buprenorphine and norbuprenorphine in rats after intravenous bolus administration of buprenorphine. European Journal of Pharmaceutical Sciences, 15(3), 287-293.
|
[15]
|
Kogel, B., Christoph, T., Straβburger, W. and Friderichs, E. (2005) Interation of μ-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice. European Journal of Pain, 9(5), 599-611.
|
[16]
|
Ohtani, M., Kotaki, H., Sawada, Y. and Iga, T. (1995) Comparative analysis of buprenorphine- & norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. Journal of Pharmacology and Experimental Therapeutics, 272(2), 505- 510.
|
[17]
|
Yassen, A., Olofsen, E., Dahan, A. and Danhof, M. (2005) Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics. Journal of Pharmacology and Experimental Therapeutics, 313(3), 1136-1149.
|
[18]
|
Hernandez-Delgadillo, G.P. and Cruz, S.L. (2006) Endogenous opioids are involved in morphine and dipyrone analgesic potentiation in the tail flick test in rats. European Journal of Pharmacology, 546(1-3), 54-59.
|
[19]
|
Shimada, S., Nakazima, Y., Yamamoto, K., Sawada, Y. and Iga, T. (1996) Comparative pharmacodynamics of eight calcium channel blocking agents in Japanese essential hypertensive patients. Biological & Pharmaceutical Bulletin, 19(3), 430-437.
|
[20]
|
Eaton1, M. (2003) Common animal models for spasticity and pain. Journal of Rehabilitation Research and Development, 40(4), 41-54.
|
[21]
|
Grumbach, L. (1996) The prediction of analgesic activity in man by animal testing. In: Knighton, R.S. and Dumke, P.R., Eds., 15th International Symposium, Detroit, 1964. Little Brown, Boston, 163-182.
|
[22]
|
Lutfy, K., Eitan, S., Bryant, CD., Yang, YC., Saliminejad, N. and Walwyn, W. (2003) Buprenorphine-induced antinociception is mediated by muopioid receptors and compromised by concomitant activation of opioid receptor- like receptors. Journal of Neuroscience, 23(32), 10331- 10337.
|
[23]
|
Villiger, J.W. and Taylor, K.M. (1981) Buprenorphine: characteristics of binding sites in the rat central nervous system. Life Science, 29(26), 2699-2708.
|
[24]
|
Cowan, A. (1995) Updaate on the general pharmacology of buprenorphin. In: Cowan, A. and Lewis J.W., Eds., Buprenorphine: Combating Drug Abuse with a Unique Opioid, Wiley-Liss, New York, 31-47.
|